Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies
NCT ID: NCT03317496
Last Updated: 2023-08-29
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE1/PHASE2
67 participants
INTERVENTIONAL
2017-12-21
2022-12-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
NCT05059522
Safety and Preliminary Efficacy of ATG-017 Monotherapy or Combination Therapy With Nivolumab in Advanced Solid Tumors and Hematological Malignancies
NCT04305249
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
NCT01772004
Study of Avelumab-M3814 Combinations
NCT03724890
Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors
NCT04344795
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Given the growing preclinical and clinical indications that combinations of anti-cancer immunotherapies potentially improve patient outcomes compared to results seen with single agents, in portions of the study to be added in the future, avelumab will be evaluated in combination with both standard-of-care chemotherapy and other anti-cancer immunotherapies in patients with advanced malignancies. Each cohort in the study will consist of a Phase 1b lead-in portion to evaluate safety and a Phase 2 cohort expansion to evaluate safety and efficacy.
In the Phase 1b safety lead-in portion, up to 12 patients will be enrolled into each cohort and evaluated for dose-limiting toxicities (DLT) during the first 2 cycles of treatment. If investigational products administration in a cohort is deemed safe in the Phase 1b lead-in, enrollment may be expanded into the Phase 2 cohort expansion. Up to approximately 40 patients in each cohort (including those enrolled in the Phase 1b lead-in and those enrolled in the Phase 2 cohort expansion) will be enrolled and treated with avelumab plus chemotherapy in the initial portion of the study and, in future portions of the study, with avelumab plus chemotherapy with or without other anti-cancer immunotherapies.
In the Phase 1b lead-in portions of NSCLC Cohort A1 and UC Cohort A2, avelumab is dosed at 800 mg fixed dose every 3 weeks. Under Protocol Amendment 4, avelumab is dosed at 1200 mg fixed dose every 3 weeks in the Phase 1b lead-in portions of NSCLC Cohort A3 and in UC Cohort A4, in combination with the same standard-of-care chemotherapy doublets used in Cohort A1 and Cohort A2, respectively. For each tumor type, the study treatment combination with the highest avelumab dose determined to be safe may be advanced into Phase 2 cohort expansion.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group A Cohort A1
Non-squamous non-small cell lung cancer (NSCLC) patients treated with 800 mg avelumab plus pemetrexed/carboplatin
Avelumab 800 mg in combination with pemetrexed / carboplatin
Avelumab Pemetrexed Carboplatin
Group A Cohort A2
Cisplatin-eligible urothelial cancer (UC)patients treated with 800 mg avelumab plus gemcitabine/cisplatin
Avelumab 800 mg in combination with gemcitabine / cisplatin.
Avelumab Gemcitabine Cisplatin
Group A Cohort A3
Non-squamous non-small cell lung cancer (NSCLC) patients treated with 1200 mg avelumab plus pemetrexed/carboplatin
Avelumab 1200 mg in combination with pemetrexed/carboplatin
Avelumab Pemetrexed Carboplatin
Group A Cohort A4
Cisplatin-eligible urothelial cancer (UC) patients treated with 1200 mg avelumab plus gemcitabine/cisplatin
Avelumab 1200 mg in combination with gemcitabine/cisplatin
Avelumab Gemcitabine Cisplatin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Avelumab 800 mg in combination with pemetrexed / carboplatin
Avelumab Pemetrexed Carboplatin
Avelumab 800 mg in combination with gemcitabine / cisplatin.
Avelumab Gemcitabine Cisplatin
Avelumab 1200 mg in combination with pemetrexed/carboplatin
Avelumab Pemetrexed Carboplatin
Avelumab 1200 mg in combination with gemcitabine/cisplatin
Avelumab Gemcitabine Cisplatin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* For all groups:
* Measurable disease by RECIST v1.1 with at least 1 measurable lesion, and availability of tumor specimen 18 months or less old.
* No prior systemic treatment for unresectable locally advanced or metastatic disease for the tumor type under study. If prior systemic chemotherapy treatment was given in the adjuvant or neo-adjuvant setting or as part of radiotherapy chemotherapy treatment, disease-free interval after stop of systemic treatment must be more than 6 months for non-squamous NSCLC and more than 12 months for UC;
* Cohort A1 and Cohort A3: Non-squamous NSCLC, with no activating EGFR mutations, ALK or ROS1 translocations/rearrangements. If monotherapy pembrolizumab is available as a standard of care treatment option, patients must have a tumor proportion score (TPS) \<50% for PD L1 (via the 22C3 pharmDx or the Ventana (SP263) PD L1 IHC assay).
* Cohort A2 and Cohort A4: Transitional cell carcinoma of the urothelium including the bladder, urethra, renal pelvis, and ureter.
2. ECOG performance status 0 or 1
3. Estimated life expectancy of at least 90 days
4. Adequate bone marrow, renal, and liver function
5. Negative serum pregnancy test at screening
6. Signed and dated informed consent
Exclusion Criteria
2. Patients with known symptomatic central nervous system metastases requiring steroids.
3. Diagnosis of other malignancy within 2 years prior to enrollment except adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the bladder, breast, or cervix, or low grade (Gleason ≤6) prostate cancer
4. Use of immunosuppressive medication at the time of enrollment
5. Active or prior autoimmune disease that might deteriorate when receiving an immuno-stimulatory agent.
6. Prior organ transplantation including allogenic stem cell transplantation
7. Active infection requiring systemic therapy
8. Known history of HIV or AIDS
9. Hepatitis B virus (HBV) or hepatitis C virus (HCV) infection at screening
10. Administration of live vaccine within 4 weeks prior to study entry
11. Known prior severe hypersensitivity to the investigational products or any component in their formulations,
12. Known prior severe hypersensitivity to platinum-related compounds for all cohorts, to pemetrexed for patients enrolled in Cohort A1 and Cohort A3, and to gemcitabine for patients enrolled in Cohort A2 and Cohort A4
13. Persisting toxicity related to prior therapy (NCI CTCAE v4.03 Grade \> 1)
14. Known history of colitis, inflammatory bowel disease, pneumonitis, pulmonary fibrosis.
15. Ongoing cardiac dysrhythmias of NCI CTCAE v4.03 Grade 2 or prolongation of the QTcF interval to \>480 msec.
16. Clinically significant (ie, active) cardiovascular disease: cerebral vascular accident/stroke (\<6 months prior to enrollment), myocardial infarction (\< 6 months prior to enrollment), unstable angina, congestive heart failure, or serious cardiac arrhythmia requiring medication.
17. Major surgery ≤28 days or major radiation therapy ≤14 days prior to enrollment.
18. Participation in other studies involving investigational drug(s) within 28 days prior to study entry.
19. Concurrent treatment with a prohibited medication.
20. Other acute or chronic medical or psychiatric condition
21. Pregnant female patients; breastfeeding female patients; fertile male patients and female patients of childbearing potential who are unwilling or unable to use at least 1 highly effective method of contraception as outlined in this protocol for the duration of the study and for at least 90 days after the last dose of chemotherapy (for male and female patients) or at least 30 days after the last dose of avelumab (for female patients), whichever is longer.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Pfizer CT.gov Call Center
Role: STUDY_DIRECTOR
Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Arizona Cancer Center - North Campus
Tucson, Arizona, United States
Banner-University Medical Center Tucson
Tucson, Arizona, United States
Stony Brook Cancer Center
Stony Brook, New York, United States
Stony Brook University
Stony Brook, New York, United States
Montefiore Medical Center - Einstein Center for Cancer Care
The Bronx, New York, United States
Montefiore Medical Center - Moses Division
The Bronx, New York, United States
Duke University Medical Center/Duke Cancer Center
Durham, North Carolina, United States
Investigational Chemotherapy Service
Durham, North Carolina, United States
Chris O'Brien Lifehouse
Camperdown, New South Wales, Australia
St Vincent's Hospital Sydney
Darlinghurst, New South Wales, Australia
St Vincent's Public Hospital Sydney
Darlinghurst, New South Wales, Australia
Western Health, Sunshine Hospital
St Albans, Victoria, Australia
Kingston Health Sciences Centre -
Kingston, Ontario, Canada
Fakultni nemocnice Olomouc, Klinika nuklearni mediciny
Olomouc, , Czechia
Fakultni nemocnice Olomouc, Ustav klinicke a molekularni patologie
Olomouc, , Czechia
Fakultni nemocnice Olomouc
Olomouc, , Czechia
Vseobecna fakultni nemocnice v Praze
Prague, , Czechia
Vseobecna fakultni nemocnice v Praze
Prague, , Czechia
Vseobecna fakultni nemocnice v Praze
Prague, , Czechia
Vseobecna fakultni nemocnice v Praze
Prague, , Czechia
Thomayerova nemocnice
Prague, , Czechia
Thomayerova nemocnice
Prague, , Czechia
Centrum nuklearni mediciny s.r.o.
Prague, , Czechia
Centrum nuklearni mediciny s.r.o.
Prague, , Czechia
Orszagos Onkologiai Intezet "C" Belgyogyaszati - Onkologiai es Klinikai Farmakologiai Osztaly
Budapest, , Hungary
AOU Ospedali Riuniti di Ancona Umberto I - GM Lancisi - G Salesi
Torrette Di Ancona, AN, Italy
IRCCS Istit.Scient.Romagnolo per lo Studio e la Cura dei Tumori
Meldola, FC, Italy
Centro di Ricerca di Fase 1, ASST Monza-Ospedale San Gerardo
Monza, MB, Italy
Oncologia, ASST Monza-Ospedale San Gerardo
Monza, MB, Italy
Istituto Europeo di Oncologia (IEO)
Milan, MI, Italy
Istituto Nazionale Tumori di Napoli IRCCS Fondazione Pascale
Napoli, , Italy
Hospital Universitario Vall d'Hebron
Barcelona, , Spain
Hospital Clinic I Provincial
Barcelona, , Spain
Hospital Universitario Fundacion Jimenez Diaz
Madrid, , Spain
Hospital Universitario 12 de Octubre
Madrid, , Spain
Fundacion Instituto Valenciano de Oncologia
Valencia, , Spain
Royal Cornwall Hospital
Truro, Cornwall, United Kingdom
The Platinum Medical Centre
London, England, United Kingdom
The Wellington Hospital - South
London, England, United Kingdom
Sarah Cannon Research Institute UK
London, England, United Kingdom
The Harley Street Clinic
London, England, United Kingdom
HCA Pharmacy Department
London, England, United Kingdom
The Harley Street Clinic
London, England, United Kingdom
The Princess Grace Hospital
London, England, United Kingdom
Weston Park Hospital
Sheffield, South Yorkshire, United Kingdom
Sir Bobby Robson Cancer Trials Research Centre
Newcastle upon Tyne, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Wheatley DA, Berardi R, Climent Duran MA, Tomiak A, Greystoke AP, Joshua AM, Arkenau HT, Geczi L, Corbacho JG, Paz-Ares LG, Hussain SA, Petruzelka L, Delmonte A, Chappey C, Masters JC, Michelon E, Murphy DA, Mwewa S, Cesari R, Doger de Speville B. First-line Avelumab plus Chemotherapy in Patients with Advanced Solid Tumors: Results from the Phase Ib/II JAVELIN Chemotherapy Medley Study. Cancer Res Commun. 2024 Jun 28;4(6):1609-1619. doi: 10.1158/2767-9764.CRC-23-0459.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Related Links
Access external resources that provide additional context or updates about the study.
To obtain contact information for a study center near you, click here.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
B9991023
Identifier Type: OTHER
Identifier Source: secondary_id
2017-001741-27
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
JAVELIN CHEMOTHERAPY MEDLEY
Identifier Type: OTHER
Identifier Source: secondary_id
B9991023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.